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Clinics and pathology 
Disease 
T-cell acute lymphoblastic leukemia (T-ALL). 
Epidemiology 
About 5% of T-ALL patients. 
Prognosis 
Currenlty, no relation between the cryptic deletion, 
del(11)(p12p13), and prognosis could be established. 
This could be due to the limited patient numbers in the 
study. 
Genetics 
Note: The cryptic deletion, del(11)(p12p13) was 
identified using microarray-based comparative genome 
hybridisation (array-CGH). The deleted region is about 
3 Mb in size and the telomeric breakpoint of these 
deletions is situated in or near the LMO2 oncogene. 
Variances in the centromeric breakpoints is detected. 
Cytogenetics 
Variants 
One of the T-ALL patients showed a cryptic deletion, 
del(11)(p12p13), that did not target the LMO2 
oncogene. Indeed, this case showed no ectopic LMO2 
expression. Therefore, this genomic region could 
potentially contain a tumor supressor gene that also 
contributes to T-ALL pathogenesis. 




LMO2 encodes a protein that participates in the 
transcription factor complex, which includes E2A, 
TAL1, GATA1, and LDB1 in erythroid cells. Within 
this transcription complex, LMO2 mediates the protein-
protein interactions by recruiting LDB1, whereas 
TAL1, GATA1, and E2A regulate the binding to 
specific DNA target sites. This complex regulates the
expression of several genes in various cellular 
backgrounds including C-KIT, EKLF, and RALDH. In 
normal T-cell development, LMO2 is expressed in 
immature CD4/CD8 double-negative thymocytes, and 
is down-regulated during T-cell maturation. 
Results of the chromosomal 
anomaly 
Hybrid gene 
Note: Ectopic expression of the LMO2 oncogene due 
to the removal of a negative regulatory element situated 
upstream of the LMO2 gene, leading to activation of 
the proximal LMO2 promoter. 
In one T-ALL case, this recurrent deletion resulted in a 
RAG2-LMO2 fusion gene, bringing the LMO2 gene 
under the control of RAG2 promoter sequences. 
However, it was shown that promoter substitution was 
not the main activational mechanism as none of the 
other del(11)(p12p13) positive cases showed a similar 
RAG2-LMO2 fusion gene. In addition, RQ-PCR 
analysis revealed that the expression of the RAG2-
LMO2 fusion is much lower than the wildtype LMO2 
expression from the proximal LMO2 gene promoter. 
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